Results 111 to 120 of about 107,932 (308)
Prospects of Antiangiogenic Therapy for Portal Hypertension in Liver Cirrhosis
Российский журнал гастроэнтерологии, гепатологии, колопроктологии, 2018 Aim. This paper is aimed at reviewing existing literature that investigates the role of angiogenesis in portal hypertension pathogenesis in liver cirrhosis and the possibilities of its antiangiogenic therapy, along with the description of angiogenesis ...
D. V. Garbuzenko
doaj +1 more source
Journal of Clinical Ultrasound, EarlyView.Shear wave elastography demonstrated moderate diagnostic accuracy for detecting congestive liver disease in patients with structural heart disease. Increased liver stiffness was associated with echocardiographic markers of venous congestion, supporting the concept that elastography may serve as a noninvasive marker of cardiohepatic interaction ...
Edinéia Camargo Dziadzio +4 more
wiley +1 more source
Ultrasound and Doppler examination capabilities in adult portal hypertension type definition
Patologìâ, 2015 Early portal hypertension type diagnostics is an ultimate factor concerning kind and tactics of treatment. Aim. To objectify ultrasound examination capabilities, portal hemodynamics were studied in 97 patients using impulse and color doppler ...
N. V. Tumanskaya +4 more
doaj +1 more source
Journal of Hepato-Biliary-Pancreatic Sciences, EarlyView.ABSTRACT Background and Purpose While normothermic machine perfusion (NMP) has benefits over static cold storage (SCS), its efficacy in high‐acuity recipients with high Model for End‐Stage Liver Disease (MELD) scores, particularly using a back‐to‐base application model, is not well established.
Yuzuru Sambommatsu +9 more
wiley +1 more source
Portal Hypertension—Noninvasive Multiparametric Ultrasound‐Based Criteria and Measurements
Portal Hypertension & CirrhosisPortal hypertension, the most common complication in liver cirrhosis, is characterized by a pathologic increase in portal venous pressure. Portal hypertension is defined as a pressure gradient greater than 5 mmHg between the portal vein and the inferior ...
Kathleen Möller +7 more
doaj +1 more source
Clinical Manifestations of Portal Hypertension
International Journal of Hepatology, 2012 The portal hypertension is responsible for many of the manifestations of liver cirrhosis. Some of these complications are the direct consequences of portal hypertension, such as gastrointestinal bleeding from ruptured gastroesophageal varices and from ...
Said A. Al-Busafi +3 more
doaj +1 more source
Hypertensive portal colopathy in schistosomiasis mansoni: proposal for a classification
Memorias do Instituto Oswaldo Cruz, 2004 Portal hypertension is a frequent complication of chronic liver disease, detected not only in schistosomiasis, but also in cirrhosis of any etiology. Vascular alterations in the colonic mucosa are a potential source for acute or chronic bleeding and have
Maria Angelina C Miranda +6 more
doaj +1 more source
Postprandial Changes in Thoracic Aortic Flow Detected by 4D Flow MRI May Influence Study Results
Journal of Magnetic Resonance Imaging, EarlyView.ABSTRACT Background While there is a growing body of data using 4D flow MRI to distinguish between normal and abnormal blood flow values in the thoracic aorta, the extent of physiological variation or lack thereof is potentially undervalued. Physiological processes such as postprandial changes to hemodynamics might influence data, normal values, follow‐
Maren Friederike Balks +11 more
wiley +1 more source
Radiological interventions in portal hypertension
, 2014 The role of radiologists in the management of portal hypertension (PHT) had been confined to its diagnosis and treatment planning. However, with the advancements in the field of interventional radiology various minimally invasive techniques have been ...
Thottan Veedu, Prasad
core +1 more source
Success of transition to adult care in patients with pediatric‐onset chronic liver disease
Journal of Pediatric Gastroenterology and Nutrition, EarlyView.Abstract Objectives Previous studies on chronic pediatric‐onset conditions have highlighted the risks of loss to follow‐up, disease progression, or therapeutic nonadherence during transition. However, very few studies have focused on liver diseases.
Sarah Mongbo +8 more
wiley +1 more source